Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorLorini, Luigi
dc.contributor.authorBescós Atin, Coro
dc.contributor.authorThavaraj, Selvam
dc.contributor.authorMüller-Richter, Urs
dc.contributor.authorAlberola Ferranti, Margarita
dc.contributor.authorPamias Romero, Jorge
dc.contributor.authorSaez barba, Manuel
dc.contributor.authorBraña Garcia, Irene
dc.contributor.authorNuciforo, Paolo Giovanni
dc.contributor.authorDe Pablo García-Cuenca, Alba
dc.contributor.authorSimonetti, Sara
dc.date.accessioned2022-04-11T10:42:41Z
dc.date.available2022-04-11T10:42:41Z
dc.date.issued2021-08
dc.identifier.citationLorini L, Bescós Atín C, Thavaraj S, Müller-Richter U, Alberola Ferranti M, Pamias Romero J, et al. Overview of oral potentially malignant disorders: From risk factors to specific therapies. Cancers. 2021 Aug;13(15):3696.
dc.identifier.issn2072-6694
dc.identifier.urihttps://hdl.handle.net/11351/7345
dc.descriptionMolecular alterations; Morphological features; Risk factors and etiology
dc.description.abstractOral squamous cell carcinoma (OSCC) is a very aggressive cancer, representing one of the most common malignancies worldwide. Oral potentially malignant disorders (OPMDs) regroup a variegate set of different histological lesions, characterized by the potential capacity to transform in OSCC. Most of the risk factors associated with OSCC are present also in OPMDs’ development; however, the molecular mechanisms and steps of malignant transformation are still unknown. Treatment of OSCC, including surgery, systemic therapy and radiotherapy (alone or in combination), has suffered a dramatic change in last years, especially with the introduction of immunotherapy. However, most cases are diagnosed during the advanced stage of the disease, decreasing drastically the survival rate of the patients. Hence, early diagnosis of premalignant conditions (OPMDs) is a priority in oral cancer, as well as a massive education about risk factors, the understanding of mechanisms involved in malignant progression and the development of specific and more efficient therapies. The aim of this article is to review epidemiological, clinical, morphological and molecular features of OPMDs, with the purpose to lay the foundation for an exhaustive comprehension of these lesions and their ability of malignant transformation and for the development of more effective and personalized treatments.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesCancers;13(15)
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectBoca - Càncer - Diagnòstic
dc.subjectCàncer - Detecció precoç
dc.subject.meshCarcinoma, Squamous Cell
dc.subject.meshEarly Detection of Cancer
dc.subject.meshMouth Neoplasms
dc.titleOverview of Oral Potentially Malignant Disorders: From Risk Factors to Specific Therapies
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/cancers13153696
dc.subject.decscarcinoma de células escamosas
dc.subject.decsdetección precoz del cáncer
dc.subject.decsneoplasias de la boca
dc.relation.publishversionhttps://doi.org/10.3390/cancers13153696
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Lorini L] Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, ASST Spedali Civili of Brescia, University of Brescia, 25123 Brescia, Italy. [Bescós Atín C, Pamias Romero J, Sáez Barba M, de Pablo García-Cuenca A] Oral and Maxillofacial Department, Vall d’Hebron University Hospital, 08035 Barcelona, Spain. [Thavaraj S] Head and Neck Pathology, Guy’s and St Thomas’ NHS Foundation Trust, London SE1 9RS, UK. [Müller-Richter U] Comprehensive Cancer Center and Department of Oral and Maxillofacial Plastic Surgery, University Hospital of Würzburg, 97070 Würzburg, Germany and Bavarian Centre for Cancer Research, 97070 Würzburg, Germany. [Alberola Ferranti M] Servei de Patologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. [Braña García I] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Nuciforo P, Simonetti S] Molecular Oncology Laboratory, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain
dc.identifier.pmid34359597
dc.identifier.wos000681805000001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record